Published in Cancer Res on August 01, 1976
Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis. Mol Cell (2012) 1.46
Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm (2010) 1.36
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther (2011) 1.32
In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One (2008) 1.27
Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles. RNA (2004) 1.15
Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release (2013) 1.12
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One (2012) 1.08
Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta (2013) 1.04
IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett (2013) 0.98
Selection and characterization of small molecules that bind the HIV-1 frameshift site RNA. ACS Chem Biol (2009) 0.98
ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. Cancer Biol Ther (2010) 0.97
Extensive podocyte loss triggers a rapid parietal epithelial cell response. J Am Soc Nephrol (2013) 0.95
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics (2012) 0.94
Experimental validation of FINDSITE(comb) virtual ligand screening results for eight proteins yields novel nanomolar and micromolar binders. J Cheminform (2014) 0.94
New functional degradable and bio-compatible nanoparticles based on poly(malic acid) derivatives for site-specific anti-cancer drug delivery. Int J Pharm (2011) 0.91
A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One (2008) 0.89
Multiplex assay for condition-dependent changes in protein-protein interactions. Proc Natl Acad Sci U S A (2012) 0.87
Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. J Cancer Res Clin Oncol (2014) 0.87
A novel use of gentamicin in the ROS-mediated sensitization of NCI-H460 lung cancer cells to various anticancer agents. ACS Chem Biol (2013) 0.87
Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin. J Proteome Res (2010) 0.85
Hydropathic analysis of the free energy differences in anthracycline antibiotic binding to DNA. Nucleic Acids Res (2003) 0.84
Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response. BMC Cardiovasc Disord (2012) 0.84
An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J Control Release (2014) 0.83
An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin. Ann Med Health Sci Res (2014) 0.83
Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci Transl Med (2014) 0.82
Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide. PLoS One (2011) 0.82
Cancer targeted therapeutics: From molecules to drug delivery vehicles. J Control Release (2015) 0.82
Nuclear mapping of nanodrug delivery systems in dynamic cellular environments. ACS Nano (2012) 0.81
A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. PLoS One (2014) 0.81
Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials (2013) 0.81
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag (2009) 0.81
Role of Dorsomedial Striatum Neuronal Ensembles in Incubation of Methamphetamine Craving after Voluntary Abstinence. J Neurosci (2017) 0.80
Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials (2015) 0.80
Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties. J Funct Biomater (2012) 0.80
Pathway analysis for drug repositioning based on public database mining. J Chem Inf Model (2014) 0.80
Intracellular distribution of anthracyclines in drug resistant cells. Cytotechnology (1998) 0.79
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. Small (2015) 0.79
Differential responses to genotoxic agents between induced pluripotent stem cells and tumor cell lines. J Hematol Oncol (2013) 0.79
Adriamycin-Induced Models of VACTERL Association. Mol Syndromol (2013) 0.78
Hypothesis: The potential application of doxorubicin against cutaneous leishmaniasis. Trop Parasitol (2015) 0.78
FAP-associated desmoid invasiveness correlates with in vitro resistance to doxorubicin. Fam Cancer (2009) 0.78
Chemophototherapy: An Emerging Treatment Option for Solid Tumors. Adv Sci (Weinh) (2016) 0.77
Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. BMC Cancer (2016) 0.77
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach. Am J Cancer Res (2012) 0.77
Identification of New Candidate Genes and Chemicals Related to Esophageal Cancer Using a Hybrid Interaction Network of Chemicals and Proteins. PLoS One (2015) 0.76
Skeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin Chemotherapy. PLoS One (2015) 0.76
Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells. J Nanosci Nanotechnol (2015) 0.76
Clinical monitoring in a patient with Friedreich ataxia and osteogenic sarcoma. J Child Neurol (2012) 0.75
The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep (2016) 0.75
Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40. Biochem Cell Biol (2015) 0.75
Investigation of the mechanisms governing doxorubicin and irinotecan release from drug-eluting beads: mathematical modeling and experimental verification. J Mater Sci Mater Med (2013) 0.75
Understanding drugs in breast cancer through drug sensitivity screening. Springerplus (2015) 0.75
Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin. Case Rep Oncol (2016) 0.75
Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy. Theranostics (2016) 0.75
tRNA binding to antitumor drug doxorubicin and its analogue. PLoS One (2013) 0.75
Establishment of an Immortalized Skin Keratinocyte Cell Line Derived from the Animal Model Mastomys coucha. PLoS One (2016) 0.75
Effects of doxorubicin administration on bone strength and quality in sedentary and physically active Wistar rats. Osteoporos Int (2016) 0.75
BCG in the treatment of acute lymphocytic leukemia. Blood (1975) 9.88
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Capnocytophaga sepsis: a newly recognised clinical entity in granulocytopenic patients. Lancet (1980) 2.55
Rapid detection of gram-negative bacterial meningitis by the limulus lysate test. N Engl J Med (1973) 2.47
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Effect of cytosine arabinoside 5'-triphosphate on mammalian DNA polymerase. Biochem Biophys Res Commun (1969) 2.16
Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res (1991) 1.77
CT in patients with scirrhous carcinoma of the GI tract: imaging findings and value for tumor detection and staging. AJR Am J Roentgenol (1995) 1.68
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61
Behavioral distress in children with cancer undergoing medical procedures: developmental considerations. J Consult Clin Psychol (1980) 1.60
A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res (1974) 1.48
Appendicitis: prospective evaluation with high-resolution CT. Radiology (1991) 1.39
Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol (1983) 1.37
Duodenal injuries caused by blunt abdominal trauma: value of CT in differentiating perforation from hematoma. AJR Am J Roentgenol (1993) 1.27
Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from childrens cancer study group. Cancer (1983) 1.26
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol (1983) 1.24
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood (1965) 1.23
Asymmetrical incorporation of amino acids in the alpha and beta chains of hemoglobin synthesized by thalassemic reticulocytes. J Lab Clin Med (1965) 1.21
Effective phototherapy in congenital nonobstructive, nonhemolytic jaundice. N Engl J Med (1970) 1.21
Cerebrospinal fluid endotoxin concentrations in gram-negative bacterial meningitis. J Pediatr (1976) 1.20
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res (1983) 1.19
Further observations on the immunofluorescence of cells in human leukemia. Cancer (1965) 1.16
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol (1993) 1.15
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res (1981) 1.15
Anxiety in the dying child. Pediatrics (1973) 1.14
Cytomegalovirus infections during acute childhood leukemia. J Infect Dis (1972) 1.13
Educational, occupational, and insurance status of childhood cancer survivors in their fourth and fifth decades of life. J Clin Oncol (1992) 1.12
Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Anticancer Res (1998) 1.11
Tracing expert thinking in clinical trial design. Comput Biomed Res (1989) 1.09
Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol (1981) 1.08
Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther (1985) 1.08
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol (1992) 1.07
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther (1985) 1.07
The synthesis of alpha, beta, and delta peptide chains by reticulocytes from subjects with thalassemia or hemoglobin Lepore. J Lab Clin Med (1967) 1.07
Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo (2001) 1.06
Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res (1985) 1.06
Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res (1997) 1.06
Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem (1968) 1.06
Phototherapy of severe unconjugated hyperbilirubinemia: formation and removal of labeled bilirubin derivatives. Pediatrics (1970) 1.05
Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer (1990) 1.04
Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery (1987) 1.04
In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res (1977) 1.04
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res (1984) 1.04
Transmission of toxoplasmosis by leukocyte transfusion. Blood (1971) 1.04
Involution of the mammalian thymus, one of the leading regulators of aging. In Vivo (1998) 1.03
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol (2001) 1.03
Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res (1983) 1.03
Pulmonary blastoma associated with cystic lung disease. Cancer (1982) 1.03
The locus of action of 1-beta-d-arabinofuranosylcytosine in the cell cycle. Cancer Res (1969) 1.03
Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol (1972) 1.03
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs (1999) 1.01
Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta (1968) 1.01
Clostridium septicum infection in childhood leukemia: report of a case and review of the literature. Cancer (1977) 1.01
Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs (1998) 1.00
Mammalian deoxynucleoside kinases. II. Deoxyadenosine kinase: purification and properties. J Biol Chem (1971) 0.99
The pseudoautosomal region and sex chromosome aneuploidies in domestic species. Sex Dev (2011) 0.99
Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo (2001) 0.98
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res (1985) 0.97
Simian virus 40 DNA replication, transcription, and antigen induction during infection with two adenovirus 2-SV40 hybrids that contain the entire SV40 genome. J Virol (1975) 0.97
Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol (1979) 0.97
Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child (1980) 0.97
Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet (1983) 0.96
Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Cancer Treat Rep (1985) 0.95
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (1984) 0.95
Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in breast carcinomas. Anticancer Res (2000) 0.95
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol (1991) 0.94
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. J Pharm Sci (1981) 0.94
A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer (1994) 0.93
L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res (1977) 0.93
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol (1998) 0.93
Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Med Pediatr Oncol (2001) 0.93
Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res (2000) 0.92
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol (1989) 0.92
Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Intern Med (1982) 0.92
Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics (1978) 0.91
The spontaneous regression of neoplasms in mammals: possible mechanisms and their application in immunotherapy. In Vivo (1998) 0.91
Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. Cancer (1991) 0.91
The role of vincristine in the treatment of childhood acute leukemia. Clin Pharmacol Ther (1966) 0.91
Primary endodermal sinus (yolk sac) tumor of the falciform ligament. J Pediatr Surg (1992) 0.90
Spinal cord toxoplasmosis in AIDS. Neurology (1989) 0.90
Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res (1994) 0.90
Studies of the kinetics of alpha and beta hemoglobin chain synthesis. J Lab Clin Med (1966) 0.89
Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res (1998) 0.89
5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood (1973) 0.89
Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Res (2001) 0.89
Spontaneous neoplastic regression: the significance of apoptosis. In Vivo (2001) 0.88
Effectiveness of vincristine (NSC-67574) against refractory leukemia in children. Cancer Chemother Rep (1968) 0.88
Hypertension in children with neurogenic tumors. Pediatrics (1983) 0.88
Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol (1979) 0.88
Fatal recurrent toxoplasmosis in a patient initially infected via a leukocyte transfusion. Am J Clin Pathol (1971) 0.87
Additive therapy in the maintenance of remission in acute lymphoblastic leukemia of childhood: the effect of the initial leukocyte count. Cancer (1974) 0.87
Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report. Cancer Treat Rep (1980) 0.87
Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo (2000) 0.87
Treatment of Pneumocystis carinii pneumonitis. A comparative trial of sulfamethoxazole-trimethoprim v pentamidine in pediatric patients with cancer: report from the Children's Cancer Study Group. Am J Dis Child (1984) 0.87
Immunocytochemical detection of homeobox B3, B4, and C6 gene product expression in lung carcinomas. Anticancer Res (2000) 0.86
Homeobox B3, B4, and C6 gene product expression in osteosarcomas as detected by immunocytochemistry. Anticancer Res (2000) 0.86
Cognitive-behavioral and pharmacologic interventions for childrens' distress during painful medical procedures. J Consult Clin Psychol (1987) 0.86
Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children. Cancer Chemother Rep (1970) 0.86
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 0.86
Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in childhood medulloblastomas/primitive neuroectodermal tumors. Anticancer Res (2000) 0.86